Pharmac Proposes Funding New Combination Therapies for CLL Blood Cancer in NZ

Associate Health Minister David Seymour and Health Minister Simeon Brown support Pharmac’s proposal to fund two new combination therapies—venetoclax with ibrutinib, and venetoclax with obinutuzumab—as first-line treatments for chronic lymphocytic leukaemia (CLL) starting May 2026. These treatments aim to improve patient outcomes by enabling longer remission, reducing the need for chemotherapy, and offering more convenient pill-based options, including availability in private clinics to minimize patient disruption. The Government’s broader commitment includes investing $604 million to fund new blood cancer medicines, expanding stem cell transplant services, and enhancing cancer care access and timeliness across New Zealand.